Javascript must be enabled to continue!
Estimating the replicability of highly cited clinical research (2004-2018)
View through CrossRef
Abstract
Introduction
Previous studies about the replicability of clinical research based on the published literature have suggested that highly cited articles are often contradicted or found to have inflated effects. Nevertheless, there are no recent updates of such efforts, and this situation may have changed over time.
Methods
We searched the Web of Science database for articles studying medical interventions with more than 2000 citations, published between 2004 and 2018 in high-impact medical journals. We then searched for replications of these studies in PubMed using the PICO (Population, Intervention, Comparator and Outcome) framework. Replication success was evaluated by the presence of a statistically significant effect in the same direction and by overlap of the replication’s effect size confidence interval (CIs) with that of the original study. Evidence of effect size inflation and potential predictors of replicability were also analyzed.
Results
A total of 89 eligible studies, of which 24 had valid replications (17 meta-analyses and 7 primary studies) were found. Of these, 21 (88%) had effect sizes with overlapping CIs. Of 15 highly cited studies with a statistically significant difference in the primary outcome, 13 (87%) had a significant effect in the replication as well. When both criteria were considered together, the replicability rate in our sample was of 20 out of 24 (83%). There was no evidence of systematic inflation in these highly cited studies, with a mean effect size ratio of 1.03 (95% CI [0.88, 1.21]) between initial and subsequent effects. Due to the small number of contradicted results, our analysis had low statistical power to detect predictors of replicability.
Conclusion
Although most studies did not have eligible replications, the replicability rate of highly cited clinical studies in our sample was higher than in previous estimates, with little evidence of systematic effect size inflation.
Title: Estimating the replicability of highly cited clinical research (2004-2018)
Description:
Abstract
Introduction
Previous studies about the replicability of clinical research based on the published literature have suggested that highly cited articles are often contradicted or found to have inflated effects.
Nevertheless, there are no recent updates of such efforts, and this situation may have changed over time.
Methods
We searched the Web of Science database for articles studying medical interventions with more than 2000 citations, published between 2004 and 2018 in high-impact medical journals.
We then searched for replications of these studies in PubMed using the PICO (Population, Intervention, Comparator and Outcome) framework.
Replication success was evaluated by the presence of a statistically significant effect in the same direction and by overlap of the replication’s effect size confidence interval (CIs) with that of the original study.
Evidence of effect size inflation and potential predictors of replicability were also analyzed.
Results
A total of 89 eligible studies, of which 24 had valid replications (17 meta-analyses and 7 primary studies) were found.
Of these, 21 (88%) had effect sizes with overlapping CIs.
Of 15 highly cited studies with a statistically significant difference in the primary outcome, 13 (87%) had a significant effect in the replication as well.
When both criteria were considered together, the replicability rate in our sample was of 20 out of 24 (83%).
There was no evidence of systematic inflation in these highly cited studies, with a mean effect size ratio of 1.
03 (95% CI [0.
88, 1.
21]) between initial and subsequent effects.
Due to the small number of contradicted results, our analysis had low statistical power to detect predictors of replicability.
Conclusion
Although most studies did not have eligible replications, the replicability rate of highly cited clinical studies in our sample was higher than in previous estimates, with little evidence of systematic effect size inflation.
Related Results
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
fMRI replicability during emotional scene viewing: Functional regions and sample size
fMRI replicability during emotional scene viewing: Functional regions and sample size
AbstractRecent findings have questioned the replicability of functional magnetic resonance imaging (fMRI) in the study of affective processing, reporting low replicability of emoti...
Factors related to the frequency of citation of epidemiologic publications
Factors related to the frequency of citation of epidemiologic publications
Abstract
Background
Previous studies have demonstrated that the frequency with which a publication is cited varies greatly. Our objective was to det...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Transparency, reproducibility, and replicability in human resource management research
Transparency, reproducibility, and replicability in human resource management research
PurposeWe address the importance of strategies for improving transparency, reproducibility, and replicability in human resource management research.Design/methodology/approachWe re...
AuPairWise: a method to estimate RNA-seq replicability through co-expression
AuPairWise: a method to estimate RNA-seq replicability through co-expression
Abstract
In addition to detecting novel transcripts and higher dynamic range, a principal claim for RNA-sequencing has been greater replicability, typically measure...
fMRI replicability depends upon sufficient individual-level data
fMRI replicability depends upon sufficient individual-level data
Abstract
The replicability of findings drawn from functional magnetic resonance imaging (fMRI) data have increasingly been called into question. Concerns have been ...

